Related Experiment Video

Updated: Apr 24, 2026

En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries
08:58

En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries

Published on: February 25, 2016

9.2K

Antiobesogenic role of endothelial nitric oxide synthase

Brian E Sansbury1, Bradford G Hill2

  • 1Diabetes and Obesity Center, Institute of Molecular Cardiology, Louisville, Kentucky, USA; Department of Physiology and Biophysics, Louisville, Kentucky, USA.

Vitamins and Hormones
|September 6, 2014
PubMed

Insights

Nitric oxide (NO) plays a key role in regulating body weight and metabolism. Enhancing NO bioavailability through endothelial NO synthase (eNOS) offers a promising therapeutic strategy for obesity and related metabolic disorders.

Area of Science:

  • Metabolic research
  • Obesity research
  • Cardiovascular disease research

Background:

  • Rising global obesity rates necessitate understanding weight gain mechanisms and developing safe anti-obesity therapies.
  • Obesity and type 2 diabetes are linked to decreased nitric oxide (NO) bioavailability, often due to endothelial NO synthase (eNOS) dysfunction.
  • Nitric oxide (NO) is a critical gaseous signaling molecule involved in regulating adiposity and systemic metabolism.

Purpose of the Study:

  • To review the metabolic actions of endothelial NO synthase (eNOS).
  • To explore the potential of eNOS-targeted therapies for combating obesity.
  • To highlight the therapeutic utility of harnessing NO's anti-obesity effects.

Main Methods:

  • Review of existing literature on nitric oxide (NO) and its role in metabolism.
  • Analysis of gain-of-function studies involving pharmacological or genetic enhancement of vascular-derived NO.
  • Examination of the link between eNOS activity, NO bioavailability, and metabolic health.

Main Results:

  • Increased NO bioavailability, achieved through enhanced eNOS activity, demonstrates significant effects on body composition and systemic metabolism.
  • Deficits in NO are characteristic of obese and diabetic states, often linked to reduced eNOS expression or activity.
  • Pharmacological and genetic approaches to increase NO production show promise in modulating adiposity.

Conclusions:

  • Endothelial NO synthase (eNOS) is a central regulator of adiposity and metabolism.
  • Strategies aimed at increasing NO bioavailability hold significant therapeutic potential for managing obesity.
  • Harnessing the metabolic actions of eNOS presents a viable avenue for developing novel anti-obesity treatments.
Keywords:
Adipose tissueDiabetesMetabolismMitochondriaNitric oxideObesity

More Related Videos

Isolation and Identification of Vascular Endothelial Cells from Distinct Adipose Depots for Downstream Applications09:00

Isolation and Identification of Vascular Endothelial Cells from Distinct Adipose Depots for Downstream Applications

Published on: June 10, 2022

2.8K
Assessing Endothelial Vasodilator Function with the Endo-PAT 200007:46

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000

Published on: October 15, 2010

45.2K

Related Concept Videos

Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.2K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.3K
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K